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Abstract
A refinement of the protonmotive Q cycle mechanism is proposed in which oxidation of ubiquinol is a concerted reaction and occurs by
an alternating, half-of-the-sites mechanism. A concerted mechanism of ubiquinol oxidation is inferred from the finding that there is reciprocal
control between the high potential and low potential redox components involved in ubiquinol oxidation. The potential of the Rieske iron–
sulfur protein controls the rate of reduction of the b cytochromes, and the potential of the b cytochromes controls the rate of reduction of the
Rieske protein and cytochrome c1. A concerted mechanism of ubiquinol oxidation reconciles the findings that the ubiquinol–cytochrome c
reductase kinetics of the bc1 complex include both a pH dependence and a dependence on Rieske iron–sulfur protein midpoint potential.
An alternating, half-of-the-sites mechanism for ubiquinol oxidation is inferred from the finding that some inhibitory analogs of ubiquinol
that block ubiquinol oxidation by binding to the ubiquinol oxidation site in the bc1 complex inhibit the yeast enzyme with a stoichiometry of
0.5 per bc1 complex. One molecule of inhibitor is sufficient to fully inhibit the dimeric enzyme, and the binding is anti-cooperative, in that a
second molecule of inhibitor binds with much lower affinity to a dimer in which an inhibitor molecule is already bound.
An alternating, half-of-the-sites mechanism implies that, at least under some conditions, only half of the sites in the dimeric enzyme are
reactive at any one time. This provides a raison d’eˆtre for the dimeric structure of the enzyme, in that bc1 activity may be regulated and
capable of switching between a half-of-the-sites active and a fully active enzyme.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Although the protonmotive Q cycle mechanism of the
cytochrome bc1 complex is generally understood [1], the
mechanism of ubiquinol oxidation at center P has not been
fully elucidated. Ubiquinol oxidation is a divergent reaction
in which electrons are transferred to the Rieske iron–sulfur
protein and to cytochrome b. It is unclear whether ubiquinol
is oxidized through a semiquinone intermediate in two
sequential reactions, or whether ubiquinol is oxidized by
the iron–sulfur protein and cytochrome bL in a concerted
reaction. There is no evidence of a semiquinone intermedi-
ate at center P. However, the predicted properties of such a
semiquinone are such that it would not exist in detectable
concentrations, and thus, the absence of semiquinone cannot
be taken as evidence for a concerted mechanism.
Crystal structures of the cytochrome bc1 complex suggest
that movement of the iron–sulfur protein is necessary for
electron transfer to cytochromes c1 and b [2]. However, both
sequential and concerted electron transfer mechanisms can
accommodate iron–sulfur protein movement. Similarly,
mechanisms that propose occupancy of two ubiquinol
molecules at center P [3,4] can be either sequential or
concerted.
The crystal structures of the cytochrome bc1 complex
also demonstrate that the enzyme is dimeric [2,5–7].
Oligomeric enzyme structures generally serve some func-
tion relevant to the enzyme mechanism. However, the Q
cycle mechanism does not require a dimeric structure, and it
is thus unclear what function is served by the bc1 dimer.
In this review, I propose that ubiquinol oxidation is a
concerted reaction and that the reaction alternates between
the two halves of the bc1 dimer. A concerted mechanism of
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ubiquinol oxidation reconciles numerous experimental
observations that otherwise seem contradictory and the
half-of-the-sites activity allows for a novel form of regu-
lation of bc1 activity that provides a raison d’eˆtre for the
dimeric structure of the enzyme.
2. Results and discussion
2.1. A concerted, alternating sites mechanism of ubiquinol
oxidation
The concerted oxidation of ubiquinol is outlined in
reactions 1a–1c in the protonmotive Q cycle shown in
Fig. 1. The concerted reaction begins when ubiquinol
replaces the ionizable proton from the imidazole nitrogen
of His-181, which is one of the ligands to the redox active
iron of the Rieske cluster [8], to form a ubiquinol–imida-
zolate complex (reaction 1a). Formation of a ubiquinol–
imidazolate complex in this manner circumvents prerequi-
site ionization of ubiquinol, which has a pKa = 11.25 [9], and
makes the reaction rate independent of the pKa of the quinol
and dependent on the pKa of the histidine imidazole group.
Formation of the ubiquinol–imidazolate complex is respon-
sible for the component of the bell-shaped activity vs. pH
curves with attributed pKa = 6.5–6.7 [10] and 7.5 [11].
The ubiquinol– imidazolate complex is the electron
donor for the iron–sulfur cluster and the bL heme. This
electron transfer does not occur unless the quinol–imida-
zolate complex forms a hydrogen bond to Glu-272 of
cytochrome b, docked within electron transfer distance of
the bL heme (reaction 1b), so that electrons are transferred
simultaneously from the quinol–imidazolate complex to the
Rieske cluster and the bL heme (reaction 1c).
A model of such a quinol– imidazolate–carboxylate
complex was generated by manually docking ubiquinol in
place of the stigmatellin residue in the stigmatellin-liganded
yeast structure as shown in Fig. 2. In this model, one quinol
hydroxyl group is hydrogen to the imidazole ring that is a
ligand to the redox active iron of the Rieske cluster, while
the other hydroxyl group is 10.5 A˚ from the porphrin ring of
heme bL. The latter distance will be a determinant of the
electron transfer rate, and some additional movement of the
docked quinol–imidazolate complex toward the bL heme is
one possible source of the relatively high activation energy
for quinol oxidation, as discussed below.
Binding of the ubiquinol only occurs when the iron–
sulfur protein is proximal to cytochrome bL, since formation
of the ubiquinol– imidazolate complex (reaction 1a) is
unfavorable unless it is docked to Glu-272 of cytochrome
b (reaction 1b). If either cytochrome bL or iron–sulfur
protein is reduced, ubiquinol oxidation cannot occur, and
ubiquinol cannot bind. As cytochrome b is reduced, the
hydrogen bond to Glu-272 is broken, allowing the proto-
nated Glu-272 to rotate toward the aqueous interface of
center P as proposed by Crofts et al. [12], while ubiquinone
dissociates (reaction 1c) as the productive complex is
dissipated. The reduced iron–sulfur protein then moves
toward cytochrome c1 and electron transfer to c1 ensues
(reaction 2 in Fig. 1). In this manner, association of
ubiquinol and dissociation of ubiquinone are linked to the
movement of the iron–sulfur protein between cytochromes
b and c1.
2.2. Evidence for a concerted mechanism of ubiquinol
oxidation
The divergent oxidation of ubiquinol at center P results
in the transient reduction of two redox centers, the iron–
sulfur cluster of the Rieske protein and the bL heme of
cytochrome b, which differ in midpoint potential by f 300
mV. The significance of this potential increment can be
appreciated from the thermodynamic profile of the Q cycle
shown in Fig. 3. Other reactions in the Q cycle, electron
transfer from bL to bH, reduction of ubiquinone to ubisemi-
quinone, and reduction of ubisemiquinone to ubiquinol
involve only modest changes in potential.
Whereas electron transfer from ubiquinol to the Rieske
cluster is significantly exergonic, electron transfer from
ubiquinol to the bL heme is usually somewhat less ender-
gonic. Ubiquinol oxidation is a concerted reaction in which
the two electron transfers are mechanistically coincident and
thermodynamically linked. The energy from reduction of
the iron–sulfur cluster is used to drive reduction of the bL
heme. The net free energy change of these two electron
transfer contributes the DG term that is used, along with the
distance to the bL heme, to calculate rates of electron
transfer by tunneling in the concerted mechanism.
We have shown that there is reciprocal control between
the high potential and low potential redox components
involved in ubiquinol oxidation at center P [16]. The
potential of the Rieske iron–sulfur protein controls the rate
of reduction of the b cytochromes, and the potential of the b
cytochromes control the rate of reduction of the Rieske
protein and cytochrome c1. The relationship between iron–
sulfur protein midpoint potential and rate of cytochrome b
reduction is shown in Fig. 4a. The iron–sulfur protein
midpoint potential was lowered by introducing mutations
into the Rieske protein that eliminate hydrogen bonds to the
iron–sulfur cluster [17]. A high resolution crystal structure
of the peripheral domain of the Rieske iron–sulfur protein
showed that the hydroxyl group of Ser-183 is hydrogen-
bonded to S-1 of the [2Fe–2S] cluster and the hydroxyl
group of Tyr-185 is hydrogen-bonded to the Sg of Cys-159,
a ligand of Fe-1 [8]. We reasoned that these hydrogen bonds
delocalize electrons out of the reduced iron–sulfur cluster,
and that if they were eliminated, the midpoint potential of
the cluster would decrease. Eliminating these two hydrogen
bonds dropped the midpoint potential of the cluster by 180
mV [17].
In the experiment shown in Fig. 4a, the bc1 complex was
reduced with menaquinol and antimycin was included to
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block reduction of cytochrome b through center N. This is
essential to insure that cytochrome b will be reduced
through center P. Under these conditions, the second order
rate constant for pre-steady state reduction of cytochrome b
decreases by approximately two orders of magnitude as the
midpoint potential of the Rieske cluster decreases by 180
mV. This decline in rate through center P accounts for the
decline in ubiquinol–cytochrome c reductase activity result-
ing from the decreased midpoint potential of the Rieske
cluster [17]. The decline in rate of b reduction also confirms
the kinetic relationship between heme bL and the Rieske
cluster implicit in the thermodynamic profile of the Q cycle
shown in Fig. 3.
The potential of the b cytochromes also controls the rate
of reduction of the Rieske protein and cytochrome c1. This
is illustrated by the results of the experiment shown in Fig.
4b. In this experiment, we examined the effects of antimycin
or ubiquinone residing at center N on the pre-steady state
rate of reduction of cytochrome c1 by menaquinol. The rates
of cytochrome c1 reduction were measured at multiple
menaquinol concentrations and second order rate constants
were calculated from the slopes of the curves in Fig. 4b.
With bc1 complex in which endogenous ubiquinone is
present, the second order rate constant for cytochrome c1
reduction declined f 4.5-fold, from 6.9 105 to 1.55 105
M  1 s 1, as the concentration of menaquinol increased.
The reason for this decline in rate constant with increasing
menaquinol concentrations is discussed below. When anti-
mycin was added, the rate constant decreased by 10-fold to
6.6 104 M  1 s 1. With the bc1 complex from the Dcoq2
mutant, the second order rate constant for c1 reduction was
1.1105 M 1 s 1, and the rate constant did not change
when antimycin was added. From these rate constants, it is
clear that in the presence of endogenous ubiquinone, anti-
mycin slows the rate of c1 reduction, but in the absence of
endogenous ubiquinone, antimycin has no effect. These
Fig. 1. The protonmotive Q cycle. Electron transfer reactions are numbered and circled. Dashed arrows designate movement of ubiquinol or ubiquinone
between centers N and P and the quinone pool and movement of the iron–sulfur protein between cytochromes b and c1. Solid black bars indicate sites of
inhibition by antimycin at center N, and by myxothiazol, MOA-stilbene, UHDBT, and stigmatellin at center P. Oxidation of ubiquinol at center P is depicted as
a concerted reaction, consisting of three component reactions, 1a–1c, shown in red. In reaction 1a, ubiquinol replaces a proton of the imidazole nitrogen of His-
181 on the Rieske iron–sulfur protein, which is a ligand to the redox active iron of the iron–sulfur cluster, to form a quinol– imidazolate complex. In reaction
1b, the quinol– imidazolate complex forms a hydrogen bond to Glu-272 of cytochrome b, docked within electron transfer distance from the bL heme. In
reaction 1c, electrons are transferred simultaneously from the quinol– imidazolate–carboxylate complex to the iron of the Rieske cluster and the bL heme,
resulting in dissociation of the complex and release of ubiquinone. The equilibria of reactions 1a and 1b lie toward the left while that of reaction 1c lies toward
the right, provided that the Rieske cluster and the bL heme are oxidized. In reaction 2, the reduced Rieske cluster oscillates to within electron transfer distance
of cytochrome c1, resulting in electron transfer from the iron–sulfur cluster to the c1 heme. Two protons are released from center P when the Rieske cluster is
oxidized by cytochrome c1 and the protonated Glu-272 of cytochrome b dissociates from the electron transfer complex and moves toward the aqueous interface
as suggested by Crofts et al. [12]. In reaction 3, an electron is transferred from the bL to bH heme, which in turn reduces ubiquinone to ubisemiquinone (reaction
4). Following oxidation of a second ubiquinol at center P and reduction of the b cytochromes, the bH heme reduces ubisemiquinone to ubiquinol (reaction 5),
accompanied by uptake of two protons at center N.
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results also indicate that absence of endogenous ubiquinone
mimics the effect of antimycin on pre-steady state reduction
of c1 by menaquinol when ubiquinone is present.
In these pre-steady state experiments, two molecules of
menaquinol are sequentially oxidized at center P. During the
first turnover, the iron–sulfur protein and cytochrome bL are
reduced (reactions 1a–1c in Fig. 1). The iron–sulfur protein
will remain predominately reduced since its potential is
higher than that of cytochrome c1. Cytochrome bL immedi-
ately reduces cytochrome bH, which then reduces ubiqui-
none to ubisemiquinone at center N (reactions 3 and 4 in
Fig. 1). The second turnover at center P is dependent upon
the redox state of cytochrome bL and the iron–sulfur
protein, and will occur only when both are oxidized.
When ubiquinone is absent or when antimycin occupies
center N, the electron introduced during the first turnover
will remain in cytochrome b and equilibrate between the bH
and bL hemes. Thus, absence of ubiquinone or the presence
of antimycin has the effect of lowering the potential of
cytochrome b after the first turnover in a pre-steady state
Fig. 2. Ubiquinol hydrogen bonded to His-181 of the Rieske iron–sulfur protein and Glu-272 of cytochrome b in the yeast cytochrome bc1 complex. The view
is from the membrane interior, looking toward center P. Ubiquinol, the bL heme, and His-181 of the Rieske protein and Glu-272 of cytochrome b are shown as
ball and stick models, with nitrogen atoms colored blue, oxygen atoms colored red, and carbon atoms colored gray. Portions of the Rieske protein and
cytochrome b are represented as green and blue strands, respectively. The iron–sulfur cluster is at the upper left, with iron and sulfur atoms colored green and
yellow. The bL heme is at the lower right, with the iron atom colored green. Dashed white lines indicate the hydrogen bonds between the quinol hydroxyl
groups and the imidazole nitrogen of His-181 of the Rieske protein and the carboxyl oxygen of Glu-272 of cytochrome b, and the distances are indicated in
Angstroms. The distance between the quinol oxygen and the bL heme is similarly indicated. Ubiquinol containing two isoprenyl groups in the side chain was
built with MacSpartan Pro (Wavefunction, Inc.) and docked manually into the Qp site by replacing stigmatellin in the coordinates for the stigmatellin-liganded
yeast enzyme [7] as described elsewhere for the chicken heart enzyme [12].
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experiment. The results in Fig. 4b show that when antimycin
is present or when ubiquinone is absent, the rate of cyto-
chrome c1 reduction is dramatically slowed. Furthermore,
antimycin had no additional slowing effect when ubiqui-
none is absent. These results show that lowering the
potential of cytochrome b by equilibration of an electron
between cytochromes bH and bL slows reduction of the
Rieske protein and cytochrome c1.
This same effect accounts for the decline in second order
rate constant for c1 reduction in the bc1 complex in the
absence of antimycin as the concentration of menaquinol
increases. As the menaquinol concentration increases, the
endogenous ubiquinone becomes partly reduced, resulting
in equilibration of an electron between ubiquinone and
Fig. 3. Thermodynamic profile of the Q cycle. The figure depicts the
thermodynamic relationship between the redox components of the yeast
cytochrome bc1 complex at pH 7, with some uncertainties and exceptions as
noted below. The redox groups are arranged vertically according to their
oxidation – reduction potentials and horizontally according to their
disposition across the inner mitochondrial membrane. The open boxes
delineate the approximate range of potentials spanned by the redox
components as their oxidation– reduction status varies in response to
changes in rates of electron transfer through the bc1 complex. The centers of
the boxes are positioned vertically at the midpoint potentials of the redox
centers. The midpoint potentials of the cytochromes and iron–sulfur
protein are those measured at room temperature for purified yeast bc1
complex at pH 7.0 [13]. Cytochrome bH is assumed to be a mixture of two
potentiometric species, as in the bovine enzyme [14]. Ubiquinone bound
proximal to the bH heme raises the potential of a portion of the bH heme to
+ 60 mV. Reduction of the quinone to quinol lowers the potential of the bH
heme to  30 mV. The potential of the ubiquinone pool is taken as 110 mV,
the value measured at liquid nitrogen temperature [13]. The potentials of the
ubisemiquinone couples at center N are estimates that assume the potential
of the invisible, anti-ferromagnetically coupled semiquinone [15] is within
range of the high potential form of cytochrome bH since this heme group
reduces both ubisemiquinone couples at center N.
Fig. 4. Reciprocal control between the high and low potential redox
components involved in ubiquinol oxidation. Panel A shows the effect of
Rieske iron–sulfur protein midpoint potential on the second order rate
constants for cytochrome b reduction, which were measured in the presence
of antimycin to insure that the reaction proceeds through center P. The
second order rate constants for cytochrome b reduction are plotted as a
function of iron–sulfur protein midpoint potential for the bc1 complexes
with the indicated iron–sulfur protein mutations. Panel B shows rates of
cytochrome c1 reduction in wild-type and ubiquinol-deficient cytochrome
bc1 complex in the absence or presence of antimycin. The rates of
cytochrome c1 reduction are plotted as a function of menaquinol
concentration for cytochrome bc1 complex from wild-type yeast (W303)
or bc1 complex from a yeast mutant lacking ubiquinone (Dcoq2), in the
presence or absence of antimycin (Ant). Dashed lines indicate the slopes
that were used to calculate two second order rate constants for the bc1
complex from the wild-type yeast (W303).
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cytochrome b. Consequently, as the concentration of mena-
quinol increases, the second order rate constant for c1
reduction in the bc1 complex in which endogenous ubiq-
uinone is present approaches the rate constants seen in the
presence of antimycin or absence of ubiquinone.
We have interpreted this reciprocal control as evidence
that oxidation of ubiquinol is a concerted reaction. However,
this can also be explained by a sequential mechanism in
which reduction of the iron–sulfur cluster by ubiquinol and
reduction of the cytochrome bL heme are thermodynami-
cally linked in an obligatory manner. In such a mechanism,
reduction of the Rieske iron–sulfur protein cannot proceed
unless the ubisemiquinone intermediate is oxidized by
reduction of cytochrome b [18–20]. The distinction
between concerted and sequentially linked mechanisms
and evidence that favors a concerted mechanism are dis-
cussed below.
2.3. Evidence for half-of-the-sites reactivity
There are numerous inhibitors of the bc1 complex that are
thought to mimic ubiquinol or ubisemiquinone and that
inhibit the enzyme by binding to the ubiquinol oxidase site
at center P. We have found that some of these inhibitors act
with a stoichiometry of 0.5 per cytochrome c1, indicating
that one molecule of inhibitor is sufficient to fully inhibit the
dimeric enzyme [21].
We used two experimental approaches to demonstrate
half-of-the-sites activity of center P inhibitors. In one, we
determined the titer for inhibition of enzyme activity, and in
the other, we determined the titer of inhibitor binding by
measuring a shift in the cytochrome b optical spectrum that
is dependent on binding of the inhibitor. The titration curves
in Fig. 5 illustrate these two types of experiments. The data
in Fig. 5a show the inhibition of yeast bc1 complex activity
with stigmatellin in an assay that measures pre-steady state
reduction of cytochrome b by menaquinol through center P.
As can be seen from the titration curve, 0.5 equivalents of
stigmatellin per bc1 complex fully inhibit this reaction. We
also determined the titer for inhibition of oxidant-induced
reduction of cytochrome b and ubiquinol–cytochrome c
reductase activity, and found that 0.5 equivalents of stigma-
tellin per bc1 complex fully inhibit these activities also [21].
The data in Fig. 5b show the shift in the optical spectrum
of cytochrome b that results from binding of MOA-stilbene,
a methoxyacrylate inhibitor that also binds to center P. As
can be seen from the titration curve, there is a progressive
increase in the magnitude of the absorbance increment until
0.5 equivalents of MOA-stilbene per bc1 complex are
bound. As additional MOA-stilbene is added, there is a
more gradual increase in the absorbance increment. This
biphasic titration curve is attributable to high affinity bind-
ing of MOA-stilbene to one half of the dimer and binding of
a second molecule of the inhibitor to the second half of the
dimer with much lower affinity. From a titration curve for
inhibition of cytochrome c reductase activity, we estimated
Ki = 2.5–5.0 nM for the high affinity binding site for MOA-
stilbene, and from the titration of the shift in the cytochrome
b optical spectrum, we estimated Kd = 1.5–2.5 AM for the
low affinity site [21].
Fig. 5. Anti-cooperative binding to half of the sites in the dimeric
cytochrome bc1 complex by inhibitory ubiquinol analogues. Panel A shows
the titration of yeast bc1 complex with stigmatellin in an assay that
measures pre-steady state reduction of cytochrome b by menaquinol
through center P. The bc1 complex was pre-mixed with 2 equivalents of
antimycin to block reduction of b through center N and then titrated with
varying amounts of stigmatellin as indicated. Pre-steady state reduction of
cytochrome b was followed at 563 nm in the stopped flow spectropho-
tometer and is plotted against the ratio of stigmatellin per bc1 complex. The
dashed lines show the linear fitting to 0.5 equivalent of inhibitor per bc1
complex. Panel B shows a titration of the red shift in the cytochrome b
spectrum that is induced by binding of MOA-stilbene. Purified cytochrome
bc1 complex from the wild-type yeast strain, W303a, was reduced with
dithionite and titrated with increasing amounts of MOA-stilbene. The inset
shows the difference spectrum resulting from the red shift in the optical
spectrum of the reduced b upon binding of MOA-stilbene and the method
used to measure the absorbance increment at 568–560 nm due to the red
shift.
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The titration curves for inhibition of cytochrome c
reductase activities and pre-steady state reduction of cyto-
chrome b indicate that one molecule of stigmatellin or
MOA-stilbene is sufficient to fully inhibit the dimeric
enzyme. In addition, the binding site of these two inhibitors
is anti-cooperative, in that a second molecule of inhibitor
binds with much lower affinity to a dimer in which an
inhibitor is already bound. As discussed above, we esti-
mated that binding of inhibitor to one site in the dimer raised
the Kd for binding at the second site approximately three
orders of magnitude [21].
We have proposed that ubiquinol binding is likewise
anti-cooperative, and that ubiquinol binding in one mono-
mer raises the Kd for ubiquinol binding in the other mono-
mer [21]. Consequently, only half of the bc1 dimer is active
at any one time, and ubiquinol oxidation alternates between
the two halves of the dimer. Elsewhere we have discussed
several reports in the literature that indicate the bc1 complex
exhibits half-of-the-sites reactivity towards ubiquinol or
inhibitory analogs [21]. To this evidence, we would add
that a crystal structure of the yeast bc1 complex co-crystal-
lized with cytochrome c shows only one molecule of
cytochrome c bound to the dimeric enzyme, and ubiquinone
is present in only half of the dimer [22].
Anti-cooperative binding of ubiquinol and inhibitory
structural analogues requires that a structural change must
be transmitted from the binding site in one monomer to the
binding site in the other. If ubiquinol oxidation is a con-
certed reaction as proposed here, ubiquinol must bridge a
nitrogen of the imidazole ring of His-181 on the Rieske
protein and the carboxyl oxygen on Glu-272 of cytochrome
b as shown in Fig. 2. In such a mechanism, it is easy to
envision how a subtle change in the distance or relative
orientation of these two residues could significantly change
the affinity for ubiquinol or structural analogues. The Rieske
iron–sulfur protein spans the bc1 dimer, with its trans-
membrane helix anchored in one monomer and its periph-
eral domain containing the iron–sulfur cluster extending
into the other dimer [2,5–7]. We have suggested that van
der Waals interactions between the Rieske protein and
cytochrome b may transmit a structural change between
the ubiquinol binding sites in the two monomers [21].
Experiments are in progress to test this possibility.
A mechanism in which only one half of the dimer is
active allows for the possibility that, under some conditions,
both halves of the dimer are active and that the activity of
the bc1 complex may be regulated by switching between a
half-of-the-sites active and a fully active enzyme. This
would have to involve a conformational change in the
enzyme that disrupts communication between the two
monomers. One can only speculate as to what types of
signals might bring about such a switch in the enzyme. It is
also possible that the bc1 dimer functions with two different
affinities for substrate, and that the second half of the dimer
is only active when the concentration of ubiquinol is high,
but kinetic evidence for this has not been seen.
2.4. Comparison to alternative mechanism
An alternative to the concerted mechanism is one con-
sisting of two sequential reactions in which reduction of the
iron–sulfur cluster by ubiquinol and reduction of the
cytochrome bL heme are thermodynamically linked in an
obligatory manner. In the ‘‘proton-gated affinity change’’
mechanism, stabilization of ubisemiquinone by anti-ferro-
magnetic coupling to the reduced iron–sulfur protein raises
the potential of the iron–sulfur cluster such that the cluster
cannot be oxidized by cytochrome c1 until the semiquinone
is oxidized [18]. In another sequentially coupled mecha-
nism, it has been proposed that the potential of the ubiq-
uinol/ubisemiquinone couple at center P is more positive
than that of the iron–sulfur cluster and that oxidation of the
semiquinone is required to lower the potential of the couple
[19,20]. The common feature of these mechanisms is that
there is a distinct ubisemiquinone intermediate, although
undetectable, and the semiquinone must be oxidized in
order to allow a thermodynamically linked reaction to occur.
In a concerted mechanism, there is no semiquinone
intermediate. According to this view, a semiquinone at
center P only exists as an aberrant by-product, resulting
from interruption of the concerted oxidation. This in turn
may lead to formation of superoxide anion, or its protonated
adduct, if the semiquinone reacts with oxygen. Formation of
superoxide anion reflects the ‘‘error rate’’ at which the
concerted reaction is disrupted.
Ubiquinol–cytochrome c reductase activity of the bc1
complex is pH-dependent, exhibiting a bell-shaped curve of
activity vs. pH, with a maximum at pH 7.5–8.0 [10,11].
Brandt and Okum [10] were the first to suggest that this
bell-shaped curve reflected opposing enhancement and
retardation of catalysis and interpreted the curve as resulting
from ionization of two functional groups with estimated
pKa = 6.5–6.7 and pKa = 9.1. They attributed the rate
enhancement at low pH to dissociation of a proton from a
proton acceptor group in the pathway of ubiquinol oxida-
tion, but did not identify the group. They attributed the
decline in activity at high pH to ionization of the imidazole
group of one of the histidine ligands to the iron–sulfur
cluster and a lowering of the midpoint potential of the
Rieske iron–sulfur cluster due to the increased negative
charge.
Covian and Moreno-Sanchez [11] have shown that the
bell-shaped pH vs. activity curve can be better fit by
assuming three protonatable groups with pKa = 5.2, 7.5,
and 9.2. They proposed that these are the carboxyl group
of Glu-272 on cytochrome b, the imidazole nitrogen on His-
181 of the Rieske protein, and the imidazole nitrogen on
His-161 of the Rieske protein, respectively. Modeling of the
bell-shaped pH vs. activity curve with three protonatable
groups in this manner better fits the pKa of His-181 deduced
from the pH dependence of the Rieske midpoint potential
[23] and agrees with the crystallographic structure implicat-
ing Glu-272 of cytochrome b in the catalytic cycle [12].
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Contributions to the catalytic rate from these three proto-
natable groups is predicted from the concerted mechanism
discussed above, since formation of the productive electron
transfer complex requires ionization of both the Glu-272
(pKa = 5.2) and the His-181 (pKa = 7.5). The concerted
mechanism also predicts a significant rate contribution from
the Rieske midpoint potential, which would account for the
declining rate associated with ionization of the His-161
imidazole group (pKa = 9.1).
The activation energy for ubiquinol oxidation is 35–45
kJ/mol at ambient temperatures [10,24]. Hong et al. [24]
have shown that the activation barrier is not formation of the
ubiquinol–imidazolate complex or movement of the Rieske
protein between cytochromes b and c1, and that the barrier
occurs after formation of the ubiquinol–imidazolate com-
plex. With these constraints, there remain two possible
sources of the high activation energy. One possible source
of the activation barrier is movement of the quinol–imida-
zolate complex closer to the bL heme after docking to Glu-
272 of cytochrome b (reaction 1b in Fig. 1). This would
shorten the 10.5-A˚ distance from the quinol oxygen to the
bL heme (Fig. 2) prior to the electron transfer (reaction 1c in
Fig. 1) and might be necessary if the DG increment between
the two electron transfers of the concerted reaction becomes
small or positive. A second possible source of the activation
barrier is movement of the Glu-272 of cytochrome b to or
from the aqueous interface. Both of these alternatives
involve a protein structural change and either could have a
relatively large activation energy, although movement of the
glutamate anion from the surface to the protein interior
seems the more likely energy-requiring step.
From the preceding discussion, it should be clear that
there are multiple kinetic and thermodynamic parameters
that contribute to the ubiquinol oxidation rate. These include
a three-component pH dependence [11], a relatively high
activation energy [10,24], reciprocal control on rates of
reduction between the bL heme and the Rieske cluster
[16], and a 2.5 /60 mV dependence of rate on potential
increment between the Rieske cluster and ubiquinol [17].
Although a sequential or a concerted mechanism can
accommodate any one of these parameters equally well, it
is hard to reconcile all of them with a sequential mechanism
in which these parameters are distributed across segregated
steps. However, all of these are incorporated into a single
step in the concerted mechanism (reactions 1a–1c in Fig. 1).
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